Integrative Single-Cell and Radiomics Analyses Identify N-Acetylneuraminate Synthase (NANS)-High Signature Associated with Adverse Prognosis and Immune Remodeling in Glioblastoma
4 affiliations
- 1Department of Neuro-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
- 2Department of Quantitative Health Sciences, Division of Computational Biology, Mayo Clinic 4500 San Pablo Road South, Jacksonville, FL 32224, USA
- 3Departments of Anatomic Pathology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
- 4Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
Abstract
Glioblastoma (GBM) is characterized by marked heterogeneity and an immunosuppressive microenvironment. N-acetylneuraminate synthase (NANS) contributes to tumor-associated metabolic regulation, but its relationship with GBM and its immune profile remains unclear. This study aimed to characterize the prognostic and immune relevance of NANS and develop an MRI radiomics model for noninvasive prediction of NANS-high GBM. Prognostic genes were screened across TCGA-GBM and two CGGA cohorts. Bulk transcriptomic and single-cell RNA sequencing analyses were used to evaluate NANS expression, patient survival association, and cellular localization. NANS-high bone marrow-derived macrophages (BMDMs) were characterized using functional enrichment and CellChat analyses. A NANS-high BMDM signature was validated in TCGA-GBM for immune infiltration and ligand–receptor axis activity. Drug sensitivity and CMap analyses were performed. MRI radiomics features were extracted from preprocessed T1 contrast-enhanced and FLAIR images, and an elastic net logistic regression model was constructed to predict NANS-high BMDM signature status. NANS was identified as a prognostic macrophage-associated biomarker in GBM and was enriched in BMDMs. NANS-high BMDMs showed enrichment of mTORC1 signaling, oxidative phosphorylation, unfolded protein response, glycolysis, hypoxia, and protein secretion programs. Cell–cell communication analysis revealed enhanced outgoing signaling toward malignant tumor states and T-cell subsets, with LGALS9-centered interactions representing the dominant differential communication program. In TCGA-GBM, the NANS-high BMDM signature correlated with increased macrophage infiltration, broad immune infiltration, and elevated LGALS9 and PLAU axis scores. Drug sensitivity analyses suggested potential vulnerabilities involving PI3K/mTOR and MAPK/ERK pathways. The radiomics model selected six MRI features and distinguished NANS-high from NANS-low tumors with an AUC of 0.795 (95% CI, 0.652–0.939); bootstrap validation showed a mean AUC of 0.793 (95% CI, 0.637–0.922). NANS-high BMDMs define a prognostically adverse and potentially targetable macrophage-associated phenotype in GBM. MRI radiomics may noninvasively predict this NANS-high BMDM state, supporting imaging-based risk stratification and therapeutic selection.
Related
- Integrative Multi-Omics and Single-Cell Analyses Identify FKBP10 as a CAF-Associated Biomarker Linked to ECM Remodeling and Aggressiveness in Neuroblastoma
- Temozolomide-associated inflammatory-repair remodeling in recurrent glioblastoma exposes a ROCK-linked therapeutic vulnerability
- Integrative single-cell and computational pathology analyses reveal a C11orf24-associated stem-like epithelial population linked to tumor microenvironment remodeling and immune evasion in bladder cancer
- Explainable DSC Perfusion Radiomics for Post-Treatment Glioblastoma Assessment Using a Soft-Voting Machine-Learning Ensemble
- Aquaporin-4 Regulates Edema, Sustains Astrocyte Differentiation, and Constrains Immunosuppressive Remodeling in Glioblastoma
BibTeX
@article{chen2026integrative,
title = {{Integrative Single-Cell and Radiomics Analyses Identify N-Acetylneuraminate Synthase (NANS)-High Signature Associated with Adverse Prognosis and Immune Remodeling in Glioblastoma}},
author = {Jianan Chen and Qiong Wu and Hannah M. Cardenas and Kaitlyn N. Bernard and Anders E. Berglund and Yu Sun and Robert J. Macaulay and James J. Mulé and Arnold B. Etame},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219635},
url = {https://www.mdpi.com/1422-0067/27/21/9635},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Integrative Single-Cell and Radiomics Analyses Identify N-Acetylneuraminate Synthase (NANS)-High Signature Associated with Adverse Prognosis and Immune Remodeling in Glioblastoma
AU - Jianan Chen
AU - Qiong Wu
AU - Hannah M. Cardenas
AU - Kaitlyn N. Bernard
AU - Anders E. Berglund
AU - Yu Sun
AU - Robert J. Macaulay
AU - James J. Mulé
AU - Arnold B. Etame
PY - 2026
DA - 2026/10/28
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219635
UR - https://www.mdpi.com/1422-0067/27/21/9635
AB - Glioblastoma (GBM) is characterized by marked heterogeneity and an immunosuppressive microenvironment. N-acetylneuraminate synthase (NANS) contributes to tumor-associated metabolic regulation, but its relationship with GBM and its immune profile remains unclear. This study aimed to characterize the prognostic and immune relevance of NANS and develop an MRI radiomics model for noninvasive prediction of NANS-high GBM. Prognostic genes were screened across TCGA-GBM and two CGGA cohorts. Bulk transcriptomic and single-cell RNA sequencing analyses were used to evaluate NANS expression, patient survival association, and cellular localization. NANS-high bone marrow-derived macrophages (BMDMs) were characterized using functional enrichment and CellChat analyses. A NANS-high BMDM signature was validated in TCGA-GBM for immune infiltration and ligand–receptor axis activity. Drug sensitivity and CMap analyses were performed. MRI radiomics features were extracted from preprocessed T1 contrast-enhanced and FLAIR images, and an elastic net logistic regression model was constructed to predict NANS-high BMDM signature status. NANS was identified as a prognostic macrophage-associated biomarker in GBM and was enriched in BMDMs. NANS-high BMDMs showed enrichment of mTORC1 signaling, oxidative phosphorylation, unfolded protein response, glycolysis, hypoxia, and protein secretion programs. Cell–cell communication analysis revealed enhanced outgoing signaling toward malignant tumor states and T-cell subsets, with LGALS9-centered interactions representing the dominant differential communication program. In TCGA-GBM, the NANS-high BMDM signature correlated with increased macrophage infiltration, broad immune infiltration, and elevated LGALS9 and PLAU axis scores. Drug sensitivity analyses suggested potential vulnerabilities involving PI3K/mTOR and MAPK/ERK pathways. The radiomics model selected six MRI features and distinguished NANS-high from NANS-low tumors with an AUC of 0.795 (95% CI, 0.652–0.939); bootstrap validation showed a mean AUC of 0.793 (95% CI, 0.637–0.922). NANS-high BMDMs define a prognostically adverse and potentially targetable macrophage-associated phenotype in GBM. MRI radiomics may noninvasively predict this NANS-high BMDM state, supporting imaging-based risk stratification and therapeutic selection.
SN - 1422-0067
ER -